JP2004531523A - アデノシンａ３レセプターアゴニストによるナチュラルキラー細胞の活性化 - Google Patents

アデノシンａ３レセプターアゴニストによるナチュラルキラー細胞の活性化 Download PDF

Info

Publication number
JP2004531523A
JP2004531523A JP2002580954A JP2002580954A JP2004531523A JP 2004531523 A JP2004531523 A JP 2004531523A JP 2002580954 A JP2002580954 A JP 2002580954A JP 2002580954 A JP2002580954 A JP 2002580954A JP 2004531523 A JP2004531523 A JP 2004531523A
Authority
JP
Japan
Prior art keywords
a3rag
alkyl
cells
adenosine
meca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002580954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004531523A5 (https=
Inventor
フィッシュマン、プニナ
Original Assignee
カン−フィテ・バイオファーマ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カン−フィテ・バイオファーマ・リミテッド filed Critical カン−フィテ・バイオファーマ・リミテッド
Publication of JP2004531523A publication Critical patent/JP2004531523A/ja
Publication of JP2004531523A5 publication Critical patent/JP2004531523A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002580954A 2001-04-12 2002-04-11 アデノシンａ３レセプターアゴニストによるナチュラルキラー細胞の活性化 Withdrawn JP2004531523A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/832,818 US20040204481A1 (en) 2001-04-12 2001-04-12 Activation of natural killer cells by adenosine A3 receptor agonists
PCT/IL2002/000298 WO2002083152A1 (en) 2001-04-12 2002-04-11 Activation of natural killer cells by adenosine a3 receptor agonists

Publications (2)

Publication Number Publication Date
JP2004531523A true JP2004531523A (ja) 2004-10-14
JP2004531523A5 JP2004531523A5 (https=) 2005-06-30

Family

ID=25262686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002580954A Withdrawn JP2004531523A (ja) 2001-04-12 2002-04-11 アデノシンａ３レセプターアゴニストによるナチュラルキラー細胞の活性化

Country Status (7)

Country Link
US (1) US20040204481A1 (https=)
EP (1) EP1383515B1 (https=)
JP (1) JP2004531523A (https=)
AT (1) ATE284698T1 (https=)
DE (1) DE60202278T2 (https=)
IL (1) IL157841A0 (https=)
WO (1) WO2002083152A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2005117910A2 (en) 2004-05-26 2005-12-15 Inotek Pharmaceuticals Corporation Purine derivatives as adenosine a1 receptor agonists and methods of use thereof
PL1778239T3 (pl) * 2004-07-28 2014-01-31 Can Fite Biopharma Ltd Agoniści receptora adenozynowego A3 do leczenia zaburzeń suchego oka w tym zespołu Sjogrena
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
MX2007003271A (es) 2004-09-20 2007-06-05 Inotek Pharmaceuticals Corp Derivados de purina y metodos de uso de los mismos.
CA2585581A1 (en) * 2004-11-22 2006-05-26 King Pharmaceuticals Research & Development Inc. Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EA015683B1 (ru) 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
GB0625100D0 (en) * 2006-12-15 2007-01-24 Univ Murcia Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
WO2010065959A1 (en) * 2008-12-05 2010-06-10 Northeastern University Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy
SG182285A1 (en) 2010-01-11 2012-08-30 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
EA201290958A1 (ru) 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
CN120365435A (zh) * 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
EP3843788A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
JP7713393B2 (ja) 2019-06-21 2025-07-25 イミュニティーバイオ インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
EP4103599A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of activating regulatory t cells
US12115191B2 (en) 2020-02-11 2024-10-15 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
EP4143231A1 (en) 2020-04-29 2023-03-08 HCW Biologics, Inc. Anti-cd26 proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4507711A1 (en) 2022-04-13 2025-02-19 ImmunityBio, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121272A (en) * 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Also Published As

Publication number Publication date
DE60202278T2 (de) 2005-12-15
EP1383515A1 (en) 2004-01-28
WO2002083152A1 (en) 2002-10-24
IL157841A0 (en) 2004-03-28
ATE284698T1 (de) 2005-01-15
EP1383515B1 (en) 2004-12-15
DE60202278D1 (de) 2005-01-20
US20040204481A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
JP2004531523A (ja) アデノシンａ３レセプターアゴニストによるナチュラルキラー細胞の活性化
CA2384111C (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US20170340658A1 (en) Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
US20110218170A1 (en) Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
US9452217B2 (en) Methods for potentiating immune response for the treatment of infectious diseases and cancer
JPH10500964A (ja) ヌクレオシド一リン酸の新規の脂質エステル及び免疫抑制薬としてのその利用
JPH0349893B2 (https=)
WO1997004761A1 (en) Methods and compositions for treating cell proliferative disorders
KR20250167640A (ko) 아즈부딘 및 화학요법제를 포함한 항종양 약학적 조성물
EP2754441B1 (en) Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
HUT76322A (en) Flavin derivatives as anti-viral agents
CA2672716C (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
KR0133555B1 (ko) 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
RU2396960C2 (ru) Комбинированная противоопухолевая терапия и фармацевтические композиции для нее
WO2008109417A1 (en) Mgmt inhibitor combinations for the treatment of neoplastic disorders
WO1994017809A1 (en) Adenosine deaminase inhibitor therapies
JPH04503814A (ja) 抗マラリア組成物及び使用方法
US10828316B2 (en) Method of treating bacterial infections
US7157449B2 (en) Medicament for the treatment of diseases caused by parasitic protozoa
EP0624368A2 (en) Use of a composition for stimulating the synthesis of glutathione in the manufacture of a medicament for the treatment of acquired immune deficiency syndrome
US20170209447A1 (en) Use of PNP Inhibitor to Treat Relapse of Malignancy after Hematopoietic Stem Cell Transplant
WO2021172490A1 (ja) 組み合わせ医薬、およびピリミジン代謝拮抗剤の耐性化の予防または抑制薬
WO2022181514A1 (ja) 慢性骨髄性白血病幹細胞阻害剤
JP4571248B2 (ja) パートリシン誘導体の投与による腫瘍抑制法
WO2011109383A1 (en) Use of 2'-deoxy -4'-thiocytidine and its analogues as dna hypomethylating anticancer agents

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20050930